Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD34+ endothelial progenitor cells
- Development stage
- Unknown
- Lead developer
- Lisata Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial
01
Overview
Autologous CD34+ endothelial progenitor cells is an investigational cell therapy developed by the National Science Council of Taiwan in collaboration with Kaohsiung Chang Gung Memorial Hospital. The treatment involves the mobilization of CD34+ cells from the patient's bone marrow into the peripheral blood using granulocyte colony-stimulating factor (G-CSF), followed by leukapheresis and cell purification. The isolated CD34+ cells are then administered via intra-coronary transfusion into the heart. The mechanism of action relies on the ability of these progenitor cells to home to ischemic myocardium and promote angiogenesis and neovascularization, which improves blood supply to the heart muscle. This therapy is primarily targeted at patients with chronic ischemic heart disease and diffuse coronary artery disease who have exhausted conventional revascularization options.
- Other names
- autologous CD34+ cellsautologous CD34+ EPCsCD34+ endothelial progenitor cells
Beyond the preview
Go deeper on autologous CD34+ endothelial progenitor cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD34+ endothelial progenitor cells.